EZH2 and plasma cell myeloma: Importantly, targeting the PLUM-EZH2 interaction using steric ASOs effectively disrupts PLUM-EZH2/PRC2 complex stability and enzymatic function, re-sensitizing myeloma cells to drug treatment.